Un vaccin expérimental contre la malaria, le “Mosquirix”, a reçu vendredi l’aval de l’Agence européenne du médicament. Une première dans le monde médical même si le sérum n’est, pour l’heure, que partiellement efficace.
Nke a bụ ezigbo mbụ na ezigbo ozi ọma. Fraịdee Julaị 24, ọgwụ mgbochi ịba natara "nkwenye dị mma" site na Agencylọ Ọrụ Ọgwụ European (EMA). A na-akpọ ya "Mosquirix" ma mepụta ya site na nnukwu ọgwụ ọgwụ GlaxoSmithKline (GSK) iji kpuchido ụmụaka na-eto eto, ọkachasị n'Africa, na nnukwu ihe egwu maka ọrịa ahụ. Nke a bụ oge izizi emere ọgwụ mgbochi iji gbochie nje (Plasmodium falciparum, parasaiti nke ịba) ọ bụghị megide nje ma ọ bụ nje.
Malite: Lekwasị anya: “Ọrịa ịba gburu nwa ọ bụla na 30 sekọnd"
“Echiche a dị mma” apụtaghị ire ahịa ọbara ahụ ozugbo, kama ọ bụ ozi ọma maka ndị ọrịa, ọ bụ ọkụ ọkụ izizi mbụ tupu enwere ike ịnweta “nkwanye” maka ojiji sitere na nzukọ ụwa nke ahụike (WHO).
"Kwa afọ, ihe dịka nde mmadụ 200 na-arịa ịba […] GSK na-agba mbọ ịmịpụta ọgwụ mgbochi a ruo afọ iri atọ [….] Nke a bụ oge mbụ na-enwere ọgwụ na-eme nje." kwuru Elisabeth Van Damme, onye njikwa nkwukọrịta nke GSK otu na France 000.
"Afọ iri atọ nke GSK na-anwa ịmepe ọgwụ a" (ELISABETH VAN DAMME, GSK)
“Nchebe dị nnọọ ala”
GSK ebughị n'uche ịzụ ọgwụ ịba ọba na Europe, ma n'Africa, na ebe kachasị mma. Kwa afọ, ịba na-ebelata ọkara nde mmadụ gburugburu ụwa, gụnyere ọnụ ọgụgụ ka ukwuu n'Africa.
Mana anyị kwesịrị ịkpachara anya: maka oge a, Mosquirix abụghị panacea. "Mgbochi a na-egosi nrụpụta ọrụ [iji gbochie ọrịa ahụ] rue 50%", na-akọwapụta isi nke GSK. Naanị ihe ọ na-eche bụ ụmụ amụrụ ọhụụ gbara izu isii ruo ọnwa iri na asaa na arụmọrụ ya na-ebelata mgbe otu afọ gasịrị, chetara EMA.
Nchedo "obi umeala", dika EMA si kwuo, ya mere, ma chebe ihe niile.
N’oge a na-ebipụta nsonaazụ ndị a, otu ọkachamara na nkà mmụta ọgwụ nke ebe okpomọkụ, Nick White (Mahadum Mahidol, Thailand), kwuru, sị: “N’ikpeazụ anyị nwere ọgwụ mgbochi ịba na-arụ ọrụ, mana ọ naghị arụ ọrụ ọfụma dịka ọ na-arụ. na-ele anya na mbido ”.
"N’onwe ya, Mosquirix agaghị ekpochapụ ịba"
"Dabere na nsonaazụ nke nyocha ahụ, na CHMP [Kọmitii EMA maka Ngwa Ọgwụ Maka Ego Mmadụ] kwubiri na, n'agbanyeghị oke nrụpụta ọrụ ya, uru / ihe ọghọm nke Mosquirix dị mma," kwusiri ike na Fraịde. Agencylọ ọrụ Europe nke dị na London.
GSK, nke na-ezube ire ahịa ọgwụ a "n'ọnụ ọnụ ahịa" n'etaghị uru, na-achọpụta na ngwaahịa ya n'onwe ya abụghị "azịza zuru oke" maka ịba.
Mgbochi a ga - anọchi anya "ngwa ọrụ ọzọ na ngwa agha" megide ọrịa ịba (ụgbụ anwụnta, ahụhụ),), na-eme atụmatụ maka akụkụ ya Dr. Ọrịa ịba. " Ewere ya iche… Mosquirix agaghị ekpochapụ ịba.
Kwa ụbọchị, ịba na-egbu ihe karịrị otu puku na narị atọ. Dabere na WHO, mmadụ 1 nwụrụ na 300 site na ịba, ọkachasị n'Africa (627%) na ọkachasị ụmụaka n'okpuru 000 (2013%).
Na AFP
